Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil

• Autor(a) principal: Justino, Maria Cleonice Aguiar
• Data de Publicação: 2011
• Outros Autores: Linhares, Alexandre da Costa, Lanzieri, Tatiana. M, Miranda, Ylle, Mascarenhas, Joana D'Arc Pereira, Abreu, Erika, Guerra, Sylvia de Fátima dos Santos, Oliveira, Alessilva S. L, Silva, Veronice B. da, Sanchez, Nervo, Meyer, Nadia, Shafi, Fakrudeen, Ortega-Barria, Eduardo, Soriano-Gabarró, Montse, Colindres, Romulo E
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
• Texto Completo: https://patua.iec.gov.br/handle/iec/946
• topic: Gastroenterite / virologia; Rotavirus / isolamento & purificação; Vacinas contra Rotavirus; Hospitalização

Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.